Kestra Medical insider plans sale of 8,681 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
KESTRA MEDICAL TECHNOLOGIES, LTD. insider Alfred J Ford has filed to sell common stock under Rule 144. The planned sale covers 8,681 shares of common stock through Merrill Lynch, with an aggregate market value of $196,284.58, and is expected on July 31, 2026 on NASDAQ.
The shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. Over the past three months, Ford has already sold 5,936 shares for an aggregate sale price of $135,120.73.
Key Figures
Key Terms
Rule 144 regulatory
equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider stock sale is disclosed for KMTS in this Form 144 filing?
When is the planned Rule 144 stock sale for KMTS expected to occur?
Which broker is handling the planned KMTS Rule 144 stock sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.